Review



cut off points  (Galectin Therapeutics)

 
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 86
      Buy from Supplier

    Structured Review

    Galectin Therapeutics cut off points
    Receiver operating characteristic (ROC) curves of serum YKL-40 and Galectin-3 for predicting proliferative vitreoretinopathy (PVR) development in rhegmatogenous retinal detachment (RRD) (a) ROC curve of serum YKL-40 demonstrating good discriminative performance for predicting PVR (AUC = 0.739, 95% CI = 0.621–0.856, p = 0.001; <t>optimal</t> <t>cut-off</t> = 26.9 ng/mL, sensitivity = 68.8%, specificity = 67.6%) (b) ROC curve of serum Galectin-3 showing moderate predictive accuracy (AUC = 0.643, 95% CI = 0.510–0.777, p = 0.045; optimal cut-off = 99.7 pg/mL, sensitivity = 62.5%, specificity = 58.8%) The diagonal line represents the reference line for random classification (AUC = 0.5)
    Cut Off Points, supplied by Galectin Therapeutics, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/cut+off+points/pmc12797585-119-14-19?v=Galectin+Therapeutics
    Average 86 stars, based on 1 article reviews
    cut off points - by Bioz Stars, 2026-07
    86/100 stars

    Images

    1) Product Images from "Evaluation of serum YKL-40 and Galectin-3 as predictive biomarkers for proliferative vitreoretinopathy in rhegmatogenous retinal detachment: a prospective comparative study"

    Article Title: Evaluation of serum YKL-40 and Galectin-3 as predictive biomarkers for proliferative vitreoretinopathy in rhegmatogenous retinal detachment: a prospective comparative study

    Journal: BMC Ophthalmology

    doi: 10.1186/s12886-025-04553-3

    Receiver operating characteristic (ROC) curves of serum YKL-40 and Galectin-3 for predicting proliferative vitreoretinopathy (PVR) development in rhegmatogenous retinal detachment (RRD) (a) ROC curve of serum YKL-40 demonstrating good discriminative performance for predicting PVR (AUC = 0.739, 95% CI = 0.621–0.856, p = 0.001; optimal cut-off = 26.9 ng/mL, sensitivity = 68.8%, specificity = 67.6%) (b) ROC curve of serum Galectin-3 showing moderate predictive accuracy (AUC = 0.643, 95% CI = 0.510–0.777, p = 0.045; optimal cut-off = 99.7 pg/mL, sensitivity = 62.5%, specificity = 58.8%) The diagonal line represents the reference line for random classification (AUC = 0.5)
    Figure Legend Snippet: Receiver operating characteristic (ROC) curves of serum YKL-40 and Galectin-3 for predicting proliferative vitreoretinopathy (PVR) development in rhegmatogenous retinal detachment (RRD) (a) ROC curve of serum YKL-40 demonstrating good discriminative performance for predicting PVR (AUC = 0.739, 95% CI = 0.621–0.856, p = 0.001; optimal cut-off = 26.9 ng/mL, sensitivity = 68.8%, specificity = 67.6%) (b) ROC curve of serum Galectin-3 showing moderate predictive accuracy (AUC = 0.643, 95% CI = 0.510–0.777, p = 0.045; optimal cut-off = 99.7 pg/mL, sensitivity = 62.5%, specificity = 58.8%) The diagonal line represents the reference line for random classification (AUC = 0.5)

    Techniques Used:



    Similar Products

    cut off points  (Galectin Therapeutics)
    86
    Galectin Therapeutics cut off points
    Receiver operating characteristic (ROC) curves of serum YKL-40 and Galectin-3 for predicting proliferative vitreoretinopathy (PVR) development in rhegmatogenous retinal detachment (RRD) (a) ROC curve of serum YKL-40 demonstrating good discriminative performance for predicting PVR (AUC = 0.739, 95% CI = 0.621–0.856, p = 0.001; <t>optimal</t> <t>cut-off</t> = 26.9 ng/mL, sensitivity = 68.8%, specificity = 67.6%) (b) ROC curve of serum Galectin-3 showing moderate predictive accuracy (AUC = 0.643, 95% CI = 0.510–0.777, p = 0.045; optimal cut-off = 99.7 pg/mL, sensitivity = 62.5%, specificity = 58.8%) The diagonal line represents the reference line for random classification (AUC = 0.5)
    Cut Off Points, supplied by Galectin Therapeutics, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/cut+off+points/pmc12797585-119-14-19?v=Galectin+Therapeutics
    Average 86 stars, based on 1 article reviews
    cut off points - by Bioz Stars, 2026-07
    86/100 stars
    		  Buy from Supplier
    hypoglycaemia with pg levels below this cut-off point  (Novo Nordisk)
    90
    Novo Nordisk hypoglycaemia with pg levels below this cut-off point
    Receiver operating characteristic (ROC) curves of serum YKL-40 and Galectin-3 for predicting proliferative vitreoretinopathy (PVR) development in rhegmatogenous retinal detachment (RRD) (a) ROC curve of serum YKL-40 demonstrating good discriminative performance for predicting PVR (AUC = 0.739, 95% CI = 0.621–0.856, p = 0.001; <t>optimal</t> <t>cut-off</t> = 26.9 ng/mL, sensitivity = 68.8%, specificity = 67.6%) (b) ROC curve of serum Galectin-3 showing moderate predictive accuracy (AUC = 0.643, 95% CI = 0.510–0.777, p = 0.045; optimal cut-off = 99.7 pg/mL, sensitivity = 62.5%, specificity = 58.8%) The diagonal line represents the reference line for random classification (AUC = 0.5)
    Hypoglycaemia With Pg Levels Below This Cut Off Point, supplied by Novo Nordisk, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/cut+off+points/pmc11372653__jamainternmed___e244346___s002-1201-5-1?v=Novo+Nordisk
    Average 90 stars, based on 1 article reviews
    hypoglycaemia with pg levels below this cut-off point - by Bioz Stars, 2026-07
    90/100 stars
    		  Buy from Supplier
    ceramic membranes with cut-off points inferior to 1 kda  (Rauschert GmbH)
    90
    Rauschert GmbH ceramic membranes with cut-off points inferior to 1 kda
    Receiver operating characteristic (ROC) curves of serum YKL-40 and Galectin-3 for predicting proliferative vitreoretinopathy (PVR) development in rhegmatogenous retinal detachment (RRD) (a) ROC curve of serum YKL-40 demonstrating good discriminative performance for predicting PVR (AUC = 0.739, 95% CI = 0.621–0.856, p = 0.001; <t>optimal</t> <t>cut-off</t> = 26.9 ng/mL, sensitivity = 68.8%, specificity = 67.6%) (b) ROC curve of serum Galectin-3 showing moderate predictive accuracy (AUC = 0.643, 95% CI = 0.510–0.777, p = 0.045; optimal cut-off = 99.7 pg/mL, sensitivity = 62.5%, specificity = 58.8%) The diagonal line represents the reference line for random classification (AUC = 0.5)
    Ceramic Membranes With Cut Off Points Inferior To 1 Kda, supplied by Rauschert GmbH, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/cut+off+points/10__1016_slash_j__seppur__2024__130442-335-7-25?v=Rauschert+GmbH
    Average 90 stars, based on 1 article reviews
    ceramic membranes with cut-off points inferior to 1 kda - by Bioz Stars, 2026-07
    90/100 stars
    		  Buy from Supplier
    clinical cut-off points  (Clinical and Laboratory Standards Institute)
    90
    Clinical and Laboratory Standards Institute clinical cut-off points
    Receiver operating characteristic (ROC) curves of serum YKL-40 and Galectin-3 for predicting proliferative vitreoretinopathy (PVR) development in rhegmatogenous retinal detachment (RRD) (a) ROC curve of serum YKL-40 demonstrating good discriminative performance for predicting PVR (AUC = 0.739, 95% CI = 0.621–0.856, p = 0.001; <t>optimal</t> <t>cut-off</t> = 26.9 ng/mL, sensitivity = 68.8%, specificity = 67.6%) (b) ROC curve of serum Galectin-3 showing moderate predictive accuracy (AUC = 0.643, 95% CI = 0.510–0.777, p = 0.045; optimal cut-off = 99.7 pg/mL, sensitivity = 62.5%, specificity = 58.8%) The diagonal line represents the reference line for random classification (AUC = 0.5)
    Clinical Cut Off Points, supplied by Clinical and Laboratory Standards Institute, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/cut+off+points/pm40430723-51-7-12?v=Clinical+and+Laboratory+Standards+Institute
    Average 90 stars, based on 1 article reviews
    clinical cut-off points - by Bioz Stars, 2026-07
    90/100 stars
    		  Buy from Supplier
    janssen's specific muscle mass cut-off points  (Janssen)
    90
    Janssen janssen's specific muscle mass cut-off points
    Receiver operating characteristic (ROC) curves of serum YKL-40 and Galectin-3 for predicting proliferative vitreoretinopathy (PVR) development in rhegmatogenous retinal detachment (RRD) (a) ROC curve of serum YKL-40 demonstrating good discriminative performance for predicting PVR (AUC = 0.739, 95% CI = 0.621–0.856, p = 0.001; <t>optimal</t> <t>cut-off</t> = 26.9 ng/mL, sensitivity = 68.8%, specificity = 67.6%) (b) ROC curve of serum Galectin-3 showing moderate predictive accuracy (AUC = 0.643, 95% CI = 0.510–0.777, p = 0.045; optimal cut-off = 99.7 pg/mL, sensitivity = 62.5%, specificity = 58.8%) The diagonal line represents the reference line for random classification (AUC = 0.5)
    Janssen's Specific Muscle Mass Cut Off Points, supplied by Janssen, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/cut+off+points/pmc11679566-108-21-17?v=Janssen
    Average 90 stars, based on 1 article reviews
    janssen's specific muscle mass cut-off points - by Bioz Stars, 2026-07
    90/100 stars
    		  Buy from Supplier
    muscle atrophy cut-off points for bia  (Janssen)
    90
    Janssen muscle atrophy cut-off points for bia
    Muscle biomarkers, definitions of muscle atrophy, and myosteatosis.
    Muscle Atrophy Cut Off Points For Bia, supplied by Janssen, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/cut+off+points/pmc11677386-274-10-23?v=Janssen
    Average 90 stars, based on 1 article reviews
    muscle atrophy cut-off points for bia - by Bioz Stars, 2026-07
    90/100 stars
    		  Buy from Supplier
    muscle atrophy cut-off points  (Janssen)
    90
    Janssen muscle atrophy cut-off points
    Muscle biomarkers, definitions of muscle atrophy, and myosteatosis.
    Muscle Atrophy Cut Off Points, supplied by Janssen, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/cut+off+points/pmc11677386-274-1-23?v=Janssen
    Average 90 stars, based on 1 article reviews
    muscle atrophy cut-off points - by Bioz Stars, 2026-07
    90/100 stars
    		  Buy from Supplier
    hs-ctni cut-off points  (Abbott Laboratories)
    90
    Abbott Laboratories hs-ctni cut-off points
    Muscle biomarkers, definitions of muscle atrophy, and myosteatosis.
    Hs Ctni Cut Off Points, supplied by Abbott Laboratories, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/cut+off+points/pm39685587-35-5-1?v=Abbott+Laboratories
    Average 90 stars, based on 1 article reviews
    hs-ctni cut-off points - by Bioz Stars, 2026-07
    90/100 stars
    		  Buy from Supplier
    point-of-care lateral flow immunoassay with a tenofovir cut-off of 650 ng/ml  (UrSure Inc)
    90
    UrSure Inc point-of-care lateral flow immunoassay with a tenofovir cut-off of 650 ng/ml
    Geometric mean (95% CI—dashed lines) concentrations in plasma and urine for (a) <t>tenofovir</t> (tenofovir alafenamide; TFV TAF ), (b) emtricitabine (FTC), (c) tenofovir (tenofovir disoproxil; TFV TDF ), (d) lamivudine (3TC) and (e) dolutegravir (DTG) (Arm 1) and (f) DTG (Arm 2), during the 14 day drug intake cessation period. Plasma values are indicated with grey lines (circles) and urine values with black lines (triangles). Detectable concentrations below the assay LLQ are expressed as half-LLQ values.
    Point Of Care Lateral Flow Immunoassay With A Tenofovir Cut Off Of 650 Ng/Ml, supplied by UrSure Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/cut+off+points/pmc11215529-159-11-0?v=UrSure+Inc
    Average 90 stars, based on 1 article reviews
    point-of-care lateral flow immunoassay with a tenofovir cut-off of 650 ng/ml - by Bioz Stars, 2026-07
    90/100 stars
    		  Buy from Supplier
    cut-off points  (Greiner Bio)
    90
    Greiner Bio cut-off points
    Geometric mean (95% CI—dashed lines) concentrations in plasma and urine for (a) <t>tenofovir</t> (tenofovir alafenamide; TFV TAF ), (b) emtricitabine (FTC), (c) tenofovir (tenofovir disoproxil; TFV TDF ), (d) lamivudine (3TC) and (e) dolutegravir (DTG) (Arm 1) and (f) DTG (Arm 2), during the 14 day drug intake cessation period. Plasma values are indicated with grey lines (circles) and urine values with black lines (triangles). Detectable concentrations below the assay LLQ are expressed as half-LLQ values.
    Cut Off Points, supplied by Greiner Bio, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/cut+off+points/10__1016_slash_j__engappai__2024__108584-223-21-23?v=Greiner+Bio
    Average 90 stars, based on 1 article reviews
    cut-off points - by Bioz Stars, 2026-07
    90/100 stars
    		  Buy from Supplier

    Image Search Results


    Receiver operating characteristic (ROC) curves of serum YKL-40 and Galectin-3 for predicting proliferative vitreoretinopathy (PVR) development in rhegmatogenous retinal detachment (RRD) (a) ROC curve of serum YKL-40 demonstrating good discriminative performance for predicting PVR (AUC = 0.739, 95% CI = 0.621–0.856, p = 0.001; optimal cut-off = 26.9 ng/mL, sensitivity = 68.8%, specificity = 67.6%) (b) ROC curve of serum Galectin-3 showing moderate predictive accuracy (AUC = 0.643, 95% CI = 0.510–0.777, p = 0.045; optimal cut-off = 99.7 pg/mL, sensitivity = 62.5%, specificity = 58.8%) The diagonal line represents the reference line for random classification (AUC = 0.5)

    Journal: BMC Ophthalmology

    Article Title: Evaluation of serum YKL-40 and Galectin-3 as predictive biomarkers for proliferative vitreoretinopathy in rhegmatogenous retinal detachment: a prospective comparative study

    doi: 10.1186/s12886-025-04553-3

    Figure Lengend Snippet: Receiver operating characteristic (ROC) curves of serum YKL-40 and Galectin-3 for predicting proliferative vitreoretinopathy (PVR) development in rhegmatogenous retinal detachment (RRD) (a) ROC curve of serum YKL-40 demonstrating good discriminative performance for predicting PVR (AUC = 0.739, 95% CI = 0.621–0.856, p = 0.001; optimal cut-off = 26.9 ng/mL, sensitivity = 68.8%, specificity = 67.6%) (b) ROC curve of serum Galectin-3 showing moderate predictive accuracy (AUC = 0.643, 95% CI = 0.510–0.777, p = 0.045; optimal cut-off = 99.7 pg/mL, sensitivity = 62.5%, specificity = 58.8%) The diagonal line represents the reference line for random classification (AUC = 0.5)

    Article Snippet: Diagnostic performance was evaluated using receiver operating characteristic (ROC) curve analysis, and the optimal cut-off points for YKL-40 and Galectin-3 were determined using the Youden index.

    Techniques:

    Muscle biomarkers, definitions of muscle atrophy, and myosteatosis.

    Journal: Nutrients

    Article Title: Muscle Biomarkers in Colorectal Cancer Outpatients: Agreement Between Computed Tomography, Bioelectrical Impedance Analysis, and Nutritional Ultrasound

    doi: 10.3390/nu16244312

    Figure Lengend Snippet: Muscle biomarkers, definitions of muscle atrophy, and myosteatosis.

    Article Snippet: Using Spanish (Masanés) [ ] muscle atrophy cut-off points for BIA, muscle atrophy occurred in 38/156 cases (24.4%) and 3/156 cases (1.9%) using Janssen [ ] or Talluri equations, respectively.

    Techniques: Biomarker Discovery

    Muscle biomarkers, definitions of muscle atrophy, and myosteatosis.

    Journal: Nutrients

    Article Title: Muscle Biomarkers in Colorectal Cancer Outpatients: Agreement Between Computed Tomography, Bioelectrical Impedance Analysis, and Nutritional Ultrasound

    doi: 10.3390/nu16244312

    Figure Lengend Snippet: Muscle biomarkers, definitions of muscle atrophy, and myosteatosis.

    Article Snippet: Using Spanish (Masanés) [ ] muscle atrophy cut-off points for BIA, muscle atrophy occurred in 38/156 cases (24.4%) and 3/156 cases (1.9%) using Janssen [ ] or Talluri equations, respectively.

    Techniques: Biomarker Discovery

    Geometric mean (95% CI—dashed lines) concentrations in plasma and urine for (a) tenofovir (tenofovir alafenamide; TFV TAF ), (b) emtricitabine (FTC), (c) tenofovir (tenofovir disoproxil; TFV TDF ), (d) lamivudine (3TC) and (e) dolutegravir (DTG) (Arm 1) and (f) DTG (Arm 2), during the 14 day drug intake cessation period. Plasma values are indicated with grey lines (circles) and urine values with black lines (triangles). Detectable concentrations below the assay LLQ are expressed as half-LLQ values.

    Journal: Journal of Antimicrobial Chemotherapy

    Article Title: Tenofovir, emtricitabine, lamivudine and dolutegravir concentrations in plasma and urine following drug intake cessation in a randomized controlled directly observed pharmacokinetic trial to aid point-of-care testing

    doi: 10.1093/jac/dkae147

    Figure Lengend Snippet: Geometric mean (95% CI—dashed lines) concentrations in plasma and urine for (a) tenofovir (tenofovir alafenamide; TFV TAF ), (b) emtricitabine (FTC), (c) tenofovir (tenofovir disoproxil; TFV TDF ), (d) lamivudine (3TC) and (e) dolutegravir (DTG) (Arm 1) and (f) DTG (Arm 2), during the 14 day drug intake cessation period. Plasma values are indicated with grey lines (circles) and urine values with black lines (triangles). Detectable concentrations below the assay LLQ are expressed as half-LLQ values.

    Article Snippet: UrSure Inc. have developed a point-of-care lateral flow immunoassay with a tenofovir cut-off of 650 ng/mL, although this has not yet been tested for tenofovir alafenamide adherence.

    Techniques: Clinical Proteomics

    Geometric mean (95% CI) pharmacokinetic parameters for tenofovir, emtricitabine (Arm 1), tenofovir, lamivudine (Arm 2) and dolutegravir (both arms) in plasma and urine after 14 days drug intake cessation

    Journal: Journal of Antimicrobial Chemotherapy

    Article Title: Tenofovir, emtricitabine, lamivudine and dolutegravir concentrations in plasma and urine following drug intake cessation in a randomized controlled directly observed pharmacokinetic trial to aid point-of-care testing

    doi: 10.1093/jac/dkae147

    Figure Lengend Snippet: Geometric mean (95% CI) pharmacokinetic parameters for tenofovir, emtricitabine (Arm 1), tenofovir, lamivudine (Arm 2) and dolutegravir (both arms) in plasma and urine after 14 days drug intake cessation

    Article Snippet: UrSure Inc. have developed a point-of-care lateral flow immunoassay with a tenofovir cut-off of 650 ng/mL, although this has not yet been tested for tenofovir alafenamide adherence.

    Techniques: Clinical Proteomics

    Proportion of plasma and urine samples with NRTI [tenofovir alafenamide (TFV TAF ), tenofovir disoproxil fumarate (TFV TDF ), emtricitabine (FTC), lamivudine (3TC)] and dolutegravir (DTG) levels above the LC-MS assay LLQ. Plasma values are indicated with a solid line (circles) and urine values with a dotted line (triangles). TFV TAF = pink; TFV TDF = green; FTC = yellow; 3TC = orange; DTG = grey. The LLQs were 1 ng/mL (TFV), 5 ng/mL (FTC/3TC) and 10 ng/mL (DTG) in plasma, and 12.5 ng/mL (NRTI) and 10 ng/mL (DTG) in urine. This figure appears in colour in the online version of JAC and in black and white in the print version of JAC .

    Journal: Journal of Antimicrobial Chemotherapy

    Article Title: Tenofovir, emtricitabine, lamivudine and dolutegravir concentrations in plasma and urine following drug intake cessation in a randomized controlled directly observed pharmacokinetic trial to aid point-of-care testing

    doi: 10.1093/jac/dkae147

    Figure Lengend Snippet: Proportion of plasma and urine samples with NRTI [tenofovir alafenamide (TFV TAF ), tenofovir disoproxil fumarate (TFV TDF ), emtricitabine (FTC), lamivudine (3TC)] and dolutegravir (DTG) levels above the LC-MS assay LLQ. Plasma values are indicated with a solid line (circles) and urine values with a dotted line (triangles). TFV TAF = pink; TFV TDF = green; FTC = yellow; 3TC = orange; DTG = grey. The LLQs were 1 ng/mL (TFV), 5 ng/mL (FTC/3TC) and 10 ng/mL (DTG) in plasma, and 12.5 ng/mL (NRTI) and 10 ng/mL (DTG) in urine. This figure appears in colour in the online version of JAC and in black and white in the print version of JAC .

    Article Snippet: UrSure Inc. have developed a point-of-care lateral flow immunoassay with a tenofovir cut-off of 650 ng/mL, although this has not yet been tested for tenofovir alafenamide adherence.

    Techniques: Clinical Proteomics, Liquid Chromatography with Mass Spectroscopy

    Model-predicted geometric mean (90% CI) dolutegravir (DTG) and tenofovir disoproxil fumarate (TFV TDF ) concentrations in plasma and urine in healthy volunteers following drug intake cessation (1–3 missed doses)

    Journal: Journal of Antimicrobial Chemotherapy

    Article Title: Tenofovir, emtricitabine, lamivudine and dolutegravir concentrations in plasma and urine following drug intake cessation in a randomized controlled directly observed pharmacokinetic trial to aid point-of-care testing

    doi: 10.1093/jac/dkae147

    Figure Lengend Snippet: Model-predicted geometric mean (90% CI) dolutegravir (DTG) and tenofovir disoproxil fumarate (TFV TDF ) concentrations in plasma and urine in healthy volunteers following drug intake cessation (1–3 missed doses)

    Article Snippet: UrSure Inc. have developed a point-of-care lateral flow immunoassay with a tenofovir cut-off of 650 ng/mL, although this has not yet been tested for tenofovir alafenamide adherence.

    Techniques: Clinical Proteomics, Concentration Assay

    Proportion of urine samples with tenofovir (TFV) concentrations >1500 ng/mL [tenofovir disoproxil fumarate (TDF) and tenofovir alafenamide (TAF) dosing] or >150 ng/mL (TAF dosing). The blue dashed line shows the 1500 ng/mL threshold and the red dashed line shows the 150 ng/mL threshold. TFV TAF = pink triangles; TFV TDF = green triangles. This figure appears in colour in the online version of JAC and in black and white in the print version of JAC .

    Journal: Journal of Antimicrobial Chemotherapy

    Article Title: Tenofovir, emtricitabine, lamivudine and dolutegravir concentrations in plasma and urine following drug intake cessation in a randomized controlled directly observed pharmacokinetic trial to aid point-of-care testing

    doi: 10.1093/jac/dkae147

    Figure Lengend Snippet: Proportion of urine samples with tenofovir (TFV) concentrations >1500 ng/mL [tenofovir disoproxil fumarate (TDF) and tenofovir alafenamide (TAF) dosing] or >150 ng/mL (TAF dosing). The blue dashed line shows the 1500 ng/mL threshold and the red dashed line shows the 150 ng/mL threshold. TFV TAF = pink triangles; TFV TDF = green triangles. This figure appears in colour in the online version of JAC and in black and white in the print version of JAC .

    Article Snippet: UrSure Inc. have developed a point-of-care lateral flow immunoassay with a tenofovir cut-off of 650 ng/mL, although this has not yet been tested for tenofovir alafenamide adherence.

    Techniques: